RecallDepth

NeuMoDx Cartridge, For In Vitro Diagnostic Use on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems, Model Number 100100

Company
Neumodx Molecular Inc
Recall Initiated
May 4, 2021
Terminated
June 21, 2022
Recall Number
Z-1978-2021
Quantity
620 cases (29,760 cartridges total)
Firm Location
Ann Arbor, MI

Reason for Recall

There is a potential for false positive results when certain lots of cartridges are used in conjunction with specific assays.

Distribution

Worldwide distribution.

Lot / Code Info

GTIN: 10814278020274;  Lot Numbers: 106629 106630 106631 106632

Root Cause

Material/Component Contamination

Action Taken

URGENT MEDICAL DEVICE CORRECTION notification letters dated 5/4/21 were sent to customers. Actions Required by Customers 1. IMMEDIATELY discontinue use of the product and discard remaining inventory in accordance with your national and local safety and environmental regulations. Please contact QIAGEN Technical Service for a free-of-charge replacement of scrapped inventory. 2. Share this Medical Device Correction Notice with all users of the NeuMoDxTM Cartridges in your facility to ensure they are aware of this notice. 3. If you have already used NeuMoDxTM Cartridges from any of these lots in combination with the NeuMoDxTM SARS-CoV-2 Assay or the NeuMoDx Flu-A-B/RSV/SARS-CoV-2 Assay, please review all SARS-CoV-2 positive results to exclude erroneous diagnosis and treatment, except in those cases where alternative confirmation was obtained. Note: results for targets other than SARS-CoV-2 are not impacted by this medical device correction. 4. Complete the attached response form and return to Quality.Communications@qiagen.com to confirm receipt of this notification. We sincerely apologize for any inconvenience this may have caused and thank you in advance for your patience and cooperation. If you have any questions regarding this notice, please contact QIAGEN Technical Services at 1-800-362-7737 or techservice-na@qiagen.com

More recalls by Neumodx Molecular Inc

View all recalls by this company →